Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies

Toxicology

Volumn 279, Issue 1-3, 2011, Pages 10-18

  Amacher, David E ^a  

^a Sciadvisor Toxicology Consultant   (United States)

Author keywords

Hepatic steatosis; In vitro assays; Serum biomarkers

Indexed keywords

AMIODARONE; FAT DROPLET; PERHEXILINE; PERHEXILINE MALEATE; PLASMA PROTEIN; XENOBIOTIC AGENT;

DISEASE COURSE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SCREENING; EARLY DIAGNOSIS; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY LIVER; FIBROSIS; GOLD STANDARD; HEPATITIS; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; KUPFFER CELL; LIPID STORAGE; LIVER; LIVER CIRRHOSIS; LIVER FAILURE; LIVER INJURY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEATOSIS; TISSUE SECTION;

ANIMALS; BIOLOGICAL MARKERS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG-INDUCED LIVER INJURY; FATTY LIVER; HUMANS; MITOCHONDRIA; PHARMACEUTICAL PREPARATIONS; TOXICITY TESTS;

ANIMALIA;

EID: 78650018055     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2010.10.006     Document Type: Review

References (77)

1. Amacher D.E., Martin B.A. Tetracycline-induced steatosis in primary canine hepatocyte cultures. Fundam. Appl. Toxicol. 1997, 40:256-263.
2. Bartolomé N., Arteta B., Martínez M.J., Chico Y., Ochoa B. Kupffer cell products and interleukin 1beta directly promote VLDL secretion and apoB mRNA up-regulation in rodent hepatocytes. Innate Immun. 2008, 14:255-266.
3. Begriche K., Igoudjil A., Pessayre D., Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006, 6:1-28.
4. Bell L.N., Theodorakis J.L., Vuppalanchi R., Saxena R., Bemis K.G., Wang M., Chalasani N. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 2010, 51:111-120.
5. Berson A., De Beco V., Lettéron P., Robin M.A., Moreau C., El Kahwaji J., Verthier N., Feldmann G., Fromenty B., Pessayre D. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998, 114:764-774.
6. Cheung O., Puri P., Eicken C., Contos M.J., Mirshahi F., Maher J.W., Kellum J.M., Min H., Luketic V.A., Sanyal A.J. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008, 48:1810-1820.
7. Chitturi S., Farrell G.C. Etiopathogenesis of nonalcoholic steatohepatitis. Semin. Liver Dis. 2001, 21:27-41.
8. Cotariu D., Zaidman J.L. Valproic acid and the liver. Clin. Chem. 1988, 34:807-890.
9. Cui W., Chen S.L., Hu K.Q. Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am. J. Transl. Res. 2010, 2:95-104.
10. Day C.P., James O.F. Steatohepatitis: a tale of two "hits" ?. Gastroenterology 1998, 114:842-845.
11. Diehl A.M., Li Z.P., Lin H.Z., Yang S.Q. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005, 54:303-306.
12. Donato M.T., Martínez-Romero A., Jiménez N., Negro A., Herrera G., Castell J.V., O'Connor J.E., Gómez-Lechón M.J. Cytometric analysis for drug-induced steatosis in HepG2 cells. Chem. Biol. Interact. 2009, 181:417-423.
13. Donthamsetty S., Bhave V.S., Mitra M.S., Latendresse J.R., Mehendale H.M. Nonalcoholic fatty liver sensitizes rats to carbon tetrachloride hepatotoxicity. Hepatology 2007, 45:391-403.
14. El-Badry A.M., Breitenstein S., Jochum W., Washington K., Paradis V., Rubbia-Brandt L., Puhan M.A., Slankamenac K., Graf R., Clavien P.A. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann. Surg. 2009, 250:691-697.
15. Esau C., Davis S., Murray S.F., Yu X.X., Pandey S.K., Pear M., Watts L., Booten S.L., Graham M., McKay R., Subramaniam A., Propp S., Lollo B.A., Freier S., Bennett C.F., Bhanot S., Monia B.P. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006, 3:87-98.
16. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(2 Suppl. 1):S99-S112.
17. Farrell G.C., Teoh N.C., McCuskey R.S. Hepatic microcirculation in fatty liver disease. Anat. Rec. (Hoboken) 2008, 291:684-692.
18. Feldstein A.E., Wieckowska A., Lopez A.R., Liu Y.C., Zein N.N., McCullough A.J. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50:1072-1078.
19. Fromenty B., Fisch C., Labbe G., Degott C., Deschamps D., Berson A., Lettéron P., Pessayre D. Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J. Pharmacol. Exp. Ther. 1990, 255:1371-1376.
20. Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol. Ther. 1995, 67:101-154.
21. Fromenty B., Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J. Hepatol. 1997, 26(Suppl. 2):43-53.
22. Fujimura H., Murakami N., Kurabe M., Toriumi W. In vitro assay for drug-induced hepatosteatosis using rat primary hepatocytes, a fluorescent lipid analog and gene expression analysis. J. Appl. Toxicol. 2009, 29:356-363.
23. Grefhorst A., Hoekstra J., Derks T.G., Ouwens D.M., Baller J.F., Havinga R., Havekes L.M., Romijn J.A., Kuipers F. Acute hepatic steatosis in mice by blocking beta-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289:G592-G598.
24. Grieco A., Forgione A., Miele L., Vero V., Greco A.V., Gasbarrini A., Gasbarrini G. Fatty liver and drugs. Eur. Rev. Med. Pharmacol. Sci. 2005, 9:261-263.
25. Gudbrandsen O.A., Rost T.H., Berge R.K. Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver. J. Lip. Res. 2006, 47:2223-2232.
26. Hijona E., Hijona L., Arenas J.I., Bujanda L. Inflammatory mediators of hepatic steatosis. Mediat. Inflamm. 2010, doi:10.1155/2010/837419.
27. Hijona E., Hijona L., Larzabal M., Sarasqueta C., Aldazabal P., Arenas J., Bujanda L. Biochemical determination of lipid content in hepatic steatosis by the Soxtec method. World J. Gastroenterol. 2010, 16:1495-1499.
28. Huang W., Metlakunta A., Dedousis N., Zhang P., Sipula I., Dube J.J., Scott D.K., O'Doherty R.M. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes 2010, 59:347-357.
29. Hübscher S.G. Histological assessment of non-alcoholic fatty liver disease. Histopathology 2006, 49:450-465.
30. Jaeschke H., Gores G.J., Cederbaum A.I., Hinson J.A., Pessayre D., Lemasters J.J. Mechanisms of hepatotoxicity. Toxicol. Sci. 2002, 65:166-176.
31. Janorkar A.V., King K.R., Megeed Z., Yarmush M.L. Development of an in vitro cell culture model of hepatic steatosis using hepatocyte-derived reporter cells. Biotechnol. Bioeng. 2009, 102:1466-1474.
32. Jarrar M.H., Baranova A., Collantes R., Ranard B., Stepanova M., Bennett C., Fang Y., Elariny H., Goodman Z., Chandhoke V., Younossi Z.M. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2008, 27:412-421.
33. Jensen K., Gluud C. The Mallory body: morphological, clinical and experimental studies (Part 1 of a literature survey). Hepatology 1994, 20:1061-1077.
34. Jolly R.A., Ciurlionis R., Morfitt D., Helgren M., Patterson R., Ulrich R.G., Waring J.F. Microvesicular steatosis induced by a short chain fatty acid: effects on mitochondrial function and correlation with gene expression. Toxicol. Pathol. 2004, 32(Suppl. 2):19-25.
35. Kalhan S.C., Guo L., Edmison J., Dasarathy S., McCullough A.J., Hanson R.W., Milburn M. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 2010, doi:10.1016/j.metabol.2010.03.006.
36. Kayadibi H., Gültepe M., Yasar B., Ince A.T., Ozcan O., Ipcioglu O.M., Kurdas O.O., Bolat B., Benek Y.Z., Guveli H., Atalay S., Ozkara S., Keskin O. Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis. Dig. Dis. Sci. 2009, 54:1764-1771.
37. Kleiner D.E. The pathology of drug-induced liver injury. Semin. Liver Dis. 2009, 29:364-372.
38. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., Ferrell L.D., Liu Y.C., Torbenson M.S., Unalp-Arida A., Yeh M., McCullough A.J., Sanyal A.J. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
39. Kleiner D.E., Gaffey M.J., Sallie R., Tsokos M., Nichols L., McKenzie R., Straus S.E., Hoofnagle J.H. Histopathologic changes associated with fialuridine hepatotoxicity. Mod. Pathol. 1997, 10:192-199.
40. Kukla M., Zwirska-Korczala K., Hartleb M., Waluga M., Chwist A., Kajor M., Ciupinska-Kajor M., Berdowska A., Wozniak-Grygiel E., Buldak R. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 2010, 45:235-242.
41. Kurien B.T., Pate, l N.C., Porter A.C., Kurono S., Matsumoto H., Wang H., Scofield R.H. Determination of prolidase activity using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal. Biochem. 2004, 331:224-229.
42. Labbe G., Pessayre D., Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam. Clin. Pharmacol. 2008, 22:335-353.
43. Larosche I., Lettéron P., Fromenty B., Vadrot N., Abbey-Toby A., Feldmann G., Pessayre D., Mansouri A. Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J. Pharmacol. Exp. Ther. 2007, 321:526-535.
44. Laterza O.F., Lim L., Garrett-Engele P.W., Vlasakova K., Muniappa N., Tanaka W.K., Johnson J.M., Sina J.F., Fare T.L., Sistare F.D., Glaab W.E. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin. Chem. 2009, 55:1977-1983.
45. Lee M.H., Kim M., Lee B.H., Kim J.H., Kang K.S., Kim H.L., Yoon B.I., Chung H., Kong G., Lee M.O. Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver. Toxicol. Appl. Pharmacol. 2008, 226:271-284.
46. Lettiott C.J., López M., Curtis R.K., Parker N., Laudes M., Yeo G., Jimenez-Liñan M., Grosse J., Saha A.K., Wiggins D., Hauton D., Brand M.D., O'Rahilly S., Griffin J.L., Gibbons G.F., Vidal-Puig A. Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB J. 2005, 19:1108-1119.
47. Lettéron P., Fromenty B., Terris B., Degott C., Pessayre D. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J. Hepatol. 1996, 24:200-208.
48. Lettéron P., Sutton A., Mansouri A., Fromenty B., Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 2003, 38:133-140.
49. Lewis J.H., Mullick F., Ishak K.G., Ranard R.C., Ragsdale B., Perse R.M., Rusnock E.J., Wolke A., Benjamin S.B., Seeff L.B., et al. Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum. Pathol. 1990, 21:59-67.
50. Ma X., Holalkere N.S., Kambadakone R.A., Mino-Kenudson M., Hahn P.F., Sahani D.V. Imaging-based quantification of hepatic fat: methods and clinical applications. Radiographics 2009, 29:1253-1277.
51. Malik R., Chang M., Bhaskar K., Nasser I., Curry M., Schuppan D., Byrnes V., Afdhal N. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2009, 24:564-568.
52. McMillian M.K., Grant E.R., Zhong Z., Parker J.B., Li L., Zivin R.A., Burczynski M.E., Johnson M.D. Nile red binding to HepG2 cells: an improved assay for in vitro studies of hepatosteatosis. In Vitro Mol. Toxicol. 2001, 14:177-190.
53. Meneses-Lorente G., Watt A., Salim K., Gaskell S.J., Muniappa N., Lawrence J., Guest P.C. Identification of early proteomic markers for hepatic steatosis. Chem. Res. Toxicol. 2006, 19:986-998.
54. Mishra P., Younossi Z.M. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am. J. Gastroenterol. 2007, 102:2716-2717.
55. Neuschwander-Tetri B.A. Nontriglyceride hepatic lipotoxicity: the new paradigm for the pathogenesis of NASH. Curr. Gastroenterol. Rep. 2010, 12:49-56.
56. Neuschwander-Tetri B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52:774-788.
57. Nishino M., Hayakawa K., Nakamura Y., Morimoto T., Mukaihara S. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. Am. J. Roentgenol. 2003, 180:129-134.
58. Oleszczuk A., Spannbauer M., Tannapfel A., Blüher M., Hengstler J., Pietsch U.C., Schuhmacher A., Wittekind C., Hauss J.P., Schön M.R. Regenerative capacity differs between micro- and macrovesicular hepatic steatosis. Exp. Toxicol. Pathol. 2007, 59:205-213.
59. Portincasa P., Grattagliano I., Palmieri V.O., Palasciano G. Current pharmacological treatment of nonalcoholic fatty liver. Curr. Med. Chem. 2006, 13:2889-2900.
60. Puli S.R., Fraley M.A., Puli V., Kuperman A.B., Alpert M.A. Hepatic cirrhosis caused by low-dose oral amiodarone therapy. Am. J. Med. Sci. 2005, 330:257-261.
61. Puljiz Z., Stimac D., Kovac D., Puljiz M., Bratanić A., Kovacić V., Kardum D., Bonacin D., Hozo I. Predictors of nonalcoholic steatohepatitis in patients with elevated alanine aminotransferase activity. Coll. Antropol. 2010, 34(Suppl. 1):33-37.
62. Raja K., Thung S.N., Fiel M.I., Chang C. Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use. Semin. Liver Dis. 2009, 29:423-428.
63. Ramachandran R., Kakar S. Histological patterns in drug-induced liver disease. J. Clin. Pathol. 2009, 62:481-492.
64. Reid A.E. Nonalcoholic steatohepatitis. Gastroenterology 2001, 121:710-723.
65. Robin M.A., Descatoire V., Pessayre D., Berson A. Steatohepatitis-inducing drugs trigger cytokeratin cross-links in hepatocytes. Possible contribution to Mallory-Denk body formation. Toxicol. In Vitro 2008, 22:1511-1519.
66. Rollins G. The perils of fatty liver disease. Clin. Lab. News 2010, 36:1-4.
67. Selzner M., Clavien P.A. Fatty liver in liver transplantation and surgery. Semin. Liver Dis. 2001, 21:105-113.
68. Serviddio G., Sastre J., Bellanti F., Viña J., Vendemiale G., Altomare E. Mitochondrial involvement in non-alcoholic steatohepatitis. Mol. Aspects Med. 2008, 29:22-35.
69. Stienstra R., Saudale F., Duval C., Keshtkar S., Groener J.E., van Rooijen N., Staels B., Kersten S., Müller M. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology 2010, 51:511-522.
70. Stravitz, R.T., Sanyal, A.J., 2003. Drug-induced steatohepatitis. Clin. Liver Dis. 7, 435-451.
71. Takami Y., Uto H., Tamai T., Sato Y., Ishida Y., Morinaga H., Sakakibara Y., Moriuchi A., Oketani M., Ido A., Nakajima T., Okanoue T., Tsubouchi H. Identification of a novel biomarker for oxidative stress induced by hydrogen peroxide in primary human hepatocytes using the 2-nitrobenzenesulfenyl chloride isotope labeling method. Hepatol. Res. 2010, 40:438-445.
72. Tiniakos D.G. Liver biopsy in alcoholic and non-alcoholic steatohepatitis patients. Gastroenterol. Clin. Biol. 2009, 33:930-939.
73. Wang K., Zhang S., Marzolf B., Troisch P., Brightman A., Hu Z., Hood L.E., Galas D.J. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:4402-4407.
74. Wobser H., Dorn C., Weiss T.S., Amann T., Bollheimer C., Büttner R., Schölmerich J., Hellerbrand C. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res. 2009, 19:996-1005.
75. Yamaguchi K., Itoh Y., Yokomizo C., Nishimura T., Niimi T., Fujii H., Okanoue T., Yoshikawa T. Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice. Lab. Invest. 2010, 90:1169-1178.
76. Yamaguchi K., Yang L., McCall S., Huang J., Yu X.X., Pandey S.K., Bhanot S., Monia B.P., Li Y.X., Diehl A.M. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45:1366-1374.
77. Yoneda M., Uchiyama T., Kato S., Endo H., Fujita K., Yoneda K., Mawatari H., Iida H., Takahashi H., Kirikoshi H., Inamori M., Nozaki Y., Kobayashi N., Kubota K., Saito S., Maeyama S., Sagara M., Aburatani H., Kodama T., Nakajima A. Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). BMC Gastroenterol. 2008, 8:53.